Forecast for Vaccine Stocks After Coronavirus Pandemic Passes
Stephen Gardner, director at ETF Managers Group, explains why investors shouldn't be rushing to sell vaccine stocks like Moderna or BioNTech even as the spread of COVID-19 slows down.
More Videos
Don't Touch My Data: What Does the Future of AI Regulation Look Like?
Matt Calkins, CEO of Appian, breaks down the recent bipartisan report on AI safety and shares thoughts on future privacy enhancements needed in the space.
When The Ball Drops, Will the Dealmaking Pick Up?
Dena Jalbert, CEO of Align Business Advisory Services breaks down the biggest mergers and acquisitions of 2024, plus her predictions for 2025.
Did The Fed Make a Soft Landing in 2024 or is There Still Turbulence Ahead?
Josh Hirt, Senior U.S. Economist at Vanguard, discusses Vanguard's Global Outlook as 2024 comes to an end, plus, expectations for 2025.
What Does A Second Trump Term Mean for Your Finances?
Ted Rossman, Senior Industry Analyst at Bankrate discusses how a second Trump administration may affect the average American's finances.
Is Chip City The Next Cookie Chain Capital?
An exclusive look inside Chip City's cookie factory with CEO and co-founder Peter Phillips to see how the brand is reimagining cookies one batch at a time.
Nasdaq Helped Companies Raise Over $21 Billion in 2024: What's in Store for IPOs in 2025?
Jeff Thomas, Global Head of Listings at Nasdaq, joined Cheddar to share Nasdaq's expectations and predictions for IPO markets in 2025.
